Aktis Oncology Announces $175 Million Oversubscribed Series

Oct 1, 2024 · BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

CouponFollow Extension

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series

4 weeks from now

Oct 1, 2024 · BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

biospace.com

$175
OFF

Aktis Raises $175M To Fuel Radiopharma Drug Development

4 weeks from now

Sep 30, 2024 · Sign up for the latest from Aktis Oncology. Email address: Leave this field empty if you're human: Contact Us

aktisoncology.com

$175
OFF

Aktis Oncology Raises $175m To Advance Radiopharmaceutical …

4 weeks from now

Oct 1, 2024 · Pharmaceutical Technology

aktisoncology.com

$175
OFF

Radiopharma Start-up Raises $175 Million - Chemical

4 weeks from now

Oct 13, 2024 · Aktis Oncology, a radiopharmaceutical firm that launched in 2021, has raised $175 million in a series B financing round co-led by RA Capital Management, RTW Investments, …

acs.org

$175
OFF

Lilly-partnered Radiopharma Startup Aktis Oncology Raises $175M

4 weeks from now

Sep 30, 2024 · Sign up for the latest from Aktis Oncology. Email address: Leave this field empty if you're human: Contact Us

aktisoncology.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · Aktis Oncology Unveils $175M Series B Financing to Advance Proprietary Radio Pharma. Exec-Edge ... CHYI Chykingyoung Investment Development Holdings Inc. 6.01-1.29 ( …

yahoo.com

$1
OFF

Eli Lilly Inks Deal Worth Over $1.1B To Develop New …

4 weeks from now

May 21, 2024 · Aktis will be eligible to receive an additional $1.1 billion in royalties and other payments for hitting certain clinical, regulatory and commercial milestones. In exchange, …

radiologybusiness.com

$175
OFF

Lilly-partnered Radiopharma Startup Aktis Oncology Raises $175M

4 weeks from now

Sep 30, 2024 · Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

endpts.com

$1
OFF

Lilly Partners With Aktis, Deepening Radiopharma Investment

4 weeks from now

May 21, 2024 · Per terms announced Tuesday, Aktis could receive as much as $1.1 billion more from Lilly if certain milestones are met. Lilly is also making an equity investment in Aktis. In …

biopharmadive.com

$60
OFF

Lilly Pays Aktis $60M To Further Dial Into Radiopharma Signal

4 weeks from now

May 21, 2024 · Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets. Lilly …

fiercebiotech.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · Sign up for the latest from Aktis Oncology. Email address: Leave this field empty if you're human: Contact Us

aktisoncology.com

FAQs about Aktis Oncology Announces $175 Million Oversubscribed Series Coupon?

What happened to aktis oncology?

BOSTON, Mass. – September 30, 2024 — Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. ...

Why did aktis invest in radiopharma?

Aktis’ funding is further evidence of industry interest in radiopharma, which have enticed investors as an alternative way to precisely target tumors. The field has benefited from the success of Novartis’ radiopharma drugs Pluvicto and Lutathera, the former of which analysts predict could eventually earn over $2 billion a year. ...

What is aktis oncology?

Aktis Oncology is a clinical stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. The company’s first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. ...

How much money does aktis oncology have?

The company now has more than $300 million in cash at its disposal, which it plans to use to test alpha radiopharmaceuticals against solid tumors. Aktis Oncology uses the radioisotope actinium-225 to develop radiopharmaceutical medicines for cancer. JacobH via Getty Images ...

How does aktis oncology use actinium 225?

Aktis Oncology uses the radioisotope actinium-225 to develop radiopharmaceutical medicines for cancer. JacobH via Getty Images Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. ...

Which companies are involved in aktis?

Bristol Myers Squibb and Novartis, the latter of which has two approved radiopharmaceuticals, participated in Aktis’ $72 million Series A round three years ago. And in 2023, Merck & Co’s venture arm participated in the company’s Series A extension, which raised $84 million. ...